Filter

111 - 120 of 792 Results

  • The Semi-Sad Prospects for Controlling Employer Health Care Costs

    From Drew Altman

    In a commentary on KFF’s 27th employer health benefits survey, President and CEO Dr. Drew Altman discusses the obstacles employers face trying to control their health care costs, and the reasons why they’ve never been meaningful supporters of government cost-containment efforts. He predicts that premium increases expected next year could lead to a new wave of higher deductibles and other forms of cost sharing for the 155 million Americans who rely on employer coverage. Read…

  • Medicare Payments and Beneficiary Costs for Prescription Drug Coverage

    Issue Brief

    This March 2007 issue brief, commissioned by the Kaiser Family Foundation, provides a basic introduction to the reimbursement system for private Medicare drug plans. It explains the system of plan bidding and payment, including the special provisions for low-income enrollees, and considers how aspects of the payment system may affect the total cost of the drug benefit over time, the cost of coverage for beneficiaries and the variety and quality of available plans. Mark Merlis…

  • Medicare Chartbook

    Report

    The Medicare Chartbook includes data and background information critical to understanding the Medicare program and the challenges it faces in keeping up with the rising costs of health care and in ensuring the program s future financial security.

  • Grievance and Appeals Procedures: An Analysis of the MMA and Proposed Regulations

    Issue Brief

    This paper, by Sara Rosenbaum, J.D., Director of the Center for Health Services Research and Policy at George Washington University, examines the procedures for resolving beneficiaries' grievances and appeals under the new Medicare drug benefit. It is one in a series commissioned by the Kaiser Family Foundation that analyzes issues surrounding the implementation of the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (MMA) and the proposed regulations. Issue Brief (.pdf)

  • National Survey of Pharmacists 2006: Full Topline Results

    Poll Finding

    National Survey of Pharmacists 2006: Full Topline Results These toplines provide additional findings from a 2006 national survey of pharmacists on their views and experiences on a wide range of health care issues. Toplines (.pdf)

  • Health Care Agenda for the New Congress – Toplines

    Poll Finding

    This document includes the complete toplines from a survey of the public's attitudes regarding the health care agenda for Bush's second term and the new Congress in 2005. It assesses the relative priority placed on health-care concerns by the American public and also provides insight into public opinion on key issues likely to face the new Congress, such as implementing the Medicare drug law, controlling health care costs, reducing the nation’s uninsured population and reforming…

  • New Survey Assesses Senior’s Views of Medicare Drug Law

    Poll Finding

    New Survey Assesses Senior's Views of Medicare Drug Law Seniors are most likely to say they would turn to their doctor, pharmacist, or the Medicare program, for help in making decisions about the new Medicare drug benefit set to begin Jan. 1, 2006, according to new data from the Kaiser Health Poll Report tracking survey. The tracking survey also provides updated tracking data on seniors’ knowledge and views of the new Medicare law. Foundation President…

  • TrumpRx: What’s the Value for Customers?

    Issue Brief

    In February, the Trump administration launched TrumpRx, a government website that provides prescription drug discounts to consumers. This brief examines issues that may impact consumers, especially those with private insurance, who access drug discounts through TrumpRx.

  • Targeting Medicare Drug Benefits: Costs and Issues

    Report

    This report, written by Marilyn Moon and Matthew Storeygard of the Urban Institute, estimates the potential cost of targeting drug benefits to low-income Medicare beneficiaries and those with catastrophic drug expenses and discusses some of the key programmatic issues that could arise under this approach. The authors predict that a targeted and comprehensive drug benefit would likely help more than half of the 11.3 million low-income beneficiaries who lack drug coverage through Medicaid or an…